Sitryx Therapeutics Strengthens Leadership Team With Appointment of Ravi M. Rao as Chief Medical Officer
Sitryx Therapeutics Ltd (the “Company”), a biopharmaceutical company pioneering the field of immunometabolism, today announced the appointment of Dr. Ravi M. Rao as its Chief Medical Officer. Dr. Rao is a rheumatologist and pharmaceutical physician with over fifteen years of leadership experience in both large and mid-sized pharmaceutical and biotechnology companies with a wide range of therapeutic area expertise including immunology, metabolic medicine, and rare diseases.
“We are delighted to appoint Ravi to this new role of Chief Medical Officer at Sitryx. He has led programs across specialties in all stages of development – including through registration and launch – and his experience at GlaxoSmithKline and Roche adds important medical expertise to our team,” said Neil Weir, Chief Executive Officer of Sitryx. “Ravi will help us drive our immunometabolism programs into the clinic and build a valuable pipeline of small molecules against high-value targets for diseases with high unmet medical need.”
Dr. Rao joins Sitryx from Swedish Orphan Biovitrum, where he served as Head of Research and Development and Chief Medical Officer leading the development of several medicines in rare diseases across immunology and haematology. Prior to that, he was Chief Medical Officer of Aeglea Biotherapeutics, a company specialising in rare metabolic diseases. Previously, he held several senior positions in R&D at GlaxoSmithKline working in immunology and specialty medicines and was a Group Medical Director at Roche working in immunology development. Ravi was an academic physician-scientist at Imperial College (London) and is a Member of the Royal College of Physicians, London and an Honorary Member of the Faculty of Pharmaceutical Medicine. He received his MB. BChir from Cambridge University and his Ph.D. in vascular biology from Imperial College, completing a postdoctoral fellowship at Harvard Medical School. He is also an independent board director of DBV Technologies. Ravi will be combining his role at Sitryx with a role at Oxford Biomedica.
“I am very excited to join Sitryx at a time when the company is beginning to demonstrate the potential of its immunometabolism product engine and is preparing to transition to a clinical-stage company,” added Dr. Rao. “Sitryx is well-positioned to exploit the intersection of the immune system function and metabolism to pioneer this field. I look forward to creating meaningful, disease-modifying therapies through this approach to improve the lives of patients with autoimmune diseases and cancer.”